Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism

Medicinal Chemistry

Volumn 5, Issue 3, 2009, Pages 263-270

  Wang, Jing Fang ^a   Yan, Jing Yi ^b   Wei, Dong Qing ^b,c   Chou, Kuo Chen ^c  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c Gordon Life Science Laboratory   (United States)

Author keywords

CYP2C9; Cytochrome P 450; Metabolic mechanism; Structure activity relationship

Indexed keywords

CYTOCHROME P450 2C9; FLUOXETINE; IBUPROFEN; MEFENAMIC ACID; NAPROXEN; SUPROFEN; CYTOCHROME P450; DRUG; LIGAND;

ARTICLE; CRYSTAL STRUCTURE; DRUG METABOLISM; DRUG PROTEIN BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MUTAGENESIS; PRIORITY JOURNAL; SIMULATION; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DATABASE; SURFACE PROPERTY; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, PROTEIN; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; PROTEIN CONFORMATION; SURFACE PROPERTIES;

EID: 67651177731     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340609788185954     Document Type: Article

References (86)

1. Pachabhai, T. S.; Noronha, S. F.; Davis, S.; Shinde, V. M.; Kshirsagar, N. A.; Gogtay, N. J. Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay). BMC Clin. Pharmacol., 2006, 6, 8.
2. Gonzalez, F. J.; Skoda, R. C.; Kimura, S.; Umeno, M.; Zanger, U. M.; Nebert, D. W.; Belboin, H. V.; Hardwick, J. P.; Meyer, U. A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 1988, 331, 442-446.
3. Anzenbacher, P.; Anzenbacherova, E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol. Life Sci., 2001, 58, 737-747.
4. Haines, D. C.; Tomchick, D. R.; Machius, M.; Peterson, J. A. Pivotal role of water in the mechanism of P450BM-3. Biochemistry, 2001, 40, 13456-13465.
5. Eiselt, R.; Domanski, T. L.; Zibat, A.; Mueller, R.; Presecan-Siedel, E.; Hustert, E.; Zanger, U. M.; Brockmoller, J.; Klenk, H. P.; Meyer, U. A.; Khan, K. K.; He, Y. A.; Halpert, J. R.; Wojnowski, L. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics, 2001, 11, 447-458.
6. Kumana, C. R.; Lauder, I. J.; Chan, M.; Ko, W.; Lin, H. J. Differences in diazepam pharmacokinetics in Chinese and white Caucasians-relation to body lipid stores. Eur. J. Clin. Pharmacol., 1987, 32, 211-215.
7. Lee, C. R.; Goldstein, J. A.; Pieper, J. A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics, 2002, 12, 251-263.
8. Chou, K. C. Review: Structural bioinformatics and its impact to biomedical science. Curr. Med. Chem., 2004, 11, 2105-2134.
9. Chou, K. C. Modeling extracellular domains of GABA-A receptors: subtypes 1, 2, 3 and 5. Biochem. Biophys. Res. Commun., 2004, 316, 636-642.
10. Chou, K. C.; Wei, D. Q.; Zhong, W. Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem. Biophys. Res. Commun., 2003, 308, 148-151. (Erratum: ibid., 2003, 310, 675)
11. Li, Y.; Wei, D. Q.; Gao, W. N.; Gao, H.; Liu, B. N.; Huang, C. J.; Xu, W. R.; Liu, D. K.; Chen, H. F.; Chou, K. C. Computational approach to drug design for oxazolidinones as antibacterial agents. Med. Chem., 2007, 3, 576-582.
12. Wang, J. F.; Wei, D. Q.; Chen, C.; Li, Y. X.; Chou, K. C. Molecular modeling of two CYP2C19 SNPs and its implications for personalized drug design. Protein Pept. Lett., 2008, 15, 27-32.
13. Zhang, R.; Wei, D. Q.; Du, Q. S.; Chou, K. C. Molecular modeling studies of peptide drug candidates against SARS. Med. Chem., 2006, 2, 309-314.
14. Gao, W. N.; Wei, D. Q.; Li, Y.; Gao, H.; Xu, W. R.; Li, A. X.; Chou, K. C. Agaritine and its derivatives are potential inhibitors against HIV proteases. Med. Chem., 2007, 3, 331-336.
15. Zheng, H.; Wei, D. Q.; Zhang, R.; Wang, C.; Wei, H.; Chou, K. C. Screening for new agonists against Alzheimer's disease. Med. Chem., 2007, 3, 488-493.
16. Chou, K. C.; Nemethy, G.; Scheraga, H. A. Energetic approach to packing of alpha-helices: 2. General treatment of nonequivalent and monregular helices. J. Am. Chem. Soc., 1984, 106, 3161-3170.
17. Chou, K. C.; Maggiora, G. M.; Nemethy, G.; Scheraga, H. A. Energetic of the structure of the four-alpha-helix boundle in proteins. Proc. Natl. Acad. Sci. USA, 1988, 85, 4295-4299.
18. Sirois, S.; Wei, D. Q.; Du, Q. S.; Chou, K. C. Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points. J. Chem. Inf. Comput. Sci., 2004, 44, 1111-1122.
19. Chou, K. C.; Wei, D. Q.; Du, Q. S.; Sirois, S.; Zhong, W. Z. Review: Progress in computational approach to drug development against SARS. Curr. Med. Chem., 2006, 13, 3263-3270.
20. Chou, K. C. Energy-optimized structure of antifreeze protein and its binding mechanism. J. Mol. Biol., 1992, 223, 509-517.
21. Zhou, G. P.; Deng, M. H. Anextension of Chou's graphical rules for deriving enzyme kinetic equations to system involving parallel reaction pathways. Biochem. J., 1984, 222, 169-176.
22. Myers, D.; Palmer, G. Microcomputer tools for steady-state enzyme kinetics. Bioinformatics, 1985, 1, 105-110.
23. Chou, K. C. Graphical rules in steady and non-steady enzyme kinetics. J. Biol. Chem., 1989, 264, 12074-12079.
24. Chou, K. C. Review: Applications of graph theory to enzyme kinetics and protein folding kinetics. Steady and non-steady state systems. Biophys. Chem., 1990, 35, 1-24.
25. Althaus, I. W.; Chou, J. J.; Gonzales, A. J.; Diebel, M. R.; Chou, K. C. Kezdy, F. J.; Romero, D. L.; Aristoff, P. A.; Tarpley, W. G.; Reusser, F. Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J. Biol. Chem., 1993, 268, 6119-6124.
26. Chou, K. C.; Zhang, C. T. Diagrammatization of codon usage in 339 HIV proteins and its biological implication. AIDS Res. Hum. Retroviruses, 1992, 8, 1967-1976.
27. Althaus, I. W.; Gonzales, A. J.; Chou, J. J.; Diebel, M. R.; Chou, K. C.; Kezdy, F. J.; Romero, D. L.; Aristoff, P. A.; Tarpley, W. G.; Reusser, F. The quinoline U-78036 is a potent inhibitor of HIV-1 reverse transcriptase. J. Biol. Chem., 1993, 268, 14875-14880.
28. Althaus, I. W.; Chou, J. J.; Gonzales, A. J.; Diebel, M. R.; Chou, K. C.; Kezdy, F. J.; Romero, D. L.; Aristoff, P. A.; Tarpley, W. G.; Reusser, F. Kinetic studies with the nonnucleoside HIV-1 reverse transcriptase inhibitor U-88204E. Biochemistry, 1993, 32, 6548-6554.
29. Chou, K. C.; Kezdy, F. J.; Reusser, F. Review: Steady-state inhibition kinetics of processive nucleic acid polymerases and nucleases. Anal. Biochem., 1994, 221, 217-230.
30. Andraos, J. Kinetic plasticity and the determination of product ratios for kinetic schemes leading to multiple products without rate laws: new methods based on directed graphs. Can. J. Chem., 2008, 86, 342-357.
31. Wang, M.; Yao, J. S.; Huang, Z. D.; Xu, Z. J.; Liu, G. P.; Zhao, H. Y.; Wang, X. Y.; Wang, J.; Zhu, Y. S.; Chou, K. C. A new nucleotide-composition based fingerprint of SARS-CoV with visualization analysis. Med. Chem., 2005, 1, 39-47.
32. Xiao, X.; Shao, S.; Ding, Y.; Huang, Z.; Chen, X.; Chou, K. C. An application of gene comparative image for predicting the effect on replication ratio by HBV virus gene missense mutation. J. Theor. Biol., 2005, 235, 555-565.
33. Xiao, X.; Shao, S. H.; Chou, K. C. A probability cellular automation model for hepatitis B viral infections. Biochem. Biophys. Res. Commun., 2006, 342, 605-610.
34. Chou, K. C. Review: Low-frequency collective motion in biomacromolecules and its bioligcal functions. Biophys. Chem., 1988, 30, 3-48.
35. Chou, K. C. Low-frequency resonance and cooperativity of hemoglobm. Trends Biochem. Sci., 1989, 14, 212.
36. Chou, K. C.; Mao, B. Collective motion in DNA and its role in drug interactions. Biopolymers, 1988, 27, 1795-1815.
37. Prado-Prado, F. J.; Gonzalez-Diaz, H.; de la Vega, O. M.; Ubeira, F. M.; Chou, K. C. Unified QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antrprotozoal compounds. Bioorg. Med. Chem., 2008, 16, 5871-5880.
38. Dea-Ayuela, M A.; Perez-Castillo, Y.; Meneses-Marcel, A.; Ubeira, F. M.; Bolas-Fernandez, F.; Chou, K. C.; Gonzalez-Diaz, H. HP-lattice QSAR for dynein proteins: experimental proteomics (2D-electrophoresis, mass spectrometry) and theoretic study of a Leishmania infantum sequence. Bioorg. Med. Chem., 2008, 16, 7770-7776.
39. Du, Q. S.; Mezey, P. G.; Chou, K. C. Heuristic molecular lipophilicity potential (HMLP): a 2D-QSAR study to LADH of molecular family pyrazole and derivatives. J. Comput. Chem., 2005, 26, 461-470.
40. Du, Q. S.; Huang, R. B.; Wei, Y. T.; Du, L. Q.; Chou, K. C. Multiple filed three dimensional quantitative structure-activity relationship (MF-3D-QSAR). J. Comput. Chem., 2008, 29, 211-219.
41. Du, Q. S.; Huang, R. B.; Chou, K. C. Review: Recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. Curr. Protein Pept. Sci., 2008, 9, 248-259.
42. Du, Q. S.; Huang, R. B.; Wei, Y. T.; Pang, Z. W.; Du, L. Q.; Chou, K. C. Fragment-based quantitative structure-activity relationship (FB-QSAR) for fragment-based drug design. J. Comput. Chem., 2008, 30, 295-304.
43. Chou, K. C.; Shen, H. B. Cell-PLoc: A package of web-servers for predicting subcellular localization of proteins in various organisms. Nat. Protoc., 2008, 3, 153-162.
44. Chou, K. C.; Shen, H. B. Review: Recent progresses in protein subcellular location prediction. Anal. Biochem., 2007, 370, 1-16.
45. Jiang, X.; Wei, R.; Zhang, T. L.; Gu, Q. Using the concept of Chou's pseudo amino acid composition to predict apoptosis proteins subcellular location: an approach by approximate entropy. Protein Pept. Lett., 2008, 15, 392-396.
46. Li, F. M.; Li, Q. Z. Predicting protein subcellular location using Chou's pseudo amino acid composition and improved hybrid approach. Protein Pept. Lett., 2008, 15, 612-616.
47. Lin, H.; Ding, H.; Guo, F. B.; Zhang, A. Y.; Huang, J. Predicting subcellular localization of mycobacterial proteins by using Chou's pseudo amino acid composition. Protein Pept. Lett., 2008, 15, 739-744.
48. Ding, Y. S.; Zhang, T. L. Using Chou's pseudo amino acid composition to predict subcellular localization of apoptosis proteins: an approach with immune genetic algorithm-based ensemble classifier. Pattern Recognit. Lett., 2008, 29, 1887-1892.
49. Chou, K. C.; Shen, H. B. MemType-2L: A web server for predicting membrane proteins and their types by incorporating evolution information through Pse-PSSM. Biochem. Biophys. Res. Commun., 2007, 360, 339-345.
50. Shen, H. B.; Chou, K. C. EzyPred: A top-down approach for predicting enzyme functional classes and subclasses. Biochem. Biophys. Res. Commun., 2007, 364, 53-59.
51. Chou, K. C. Prediction of G-protein-coupled receptor classes. J. Proteome Res., 2005, 4, 1413-1418.
52. Xiao, X.; Wang, P.; Chou, K. C. GPCR-CA: A cellular automaton image approach for prediction G-protein-coupled receptor functional classes. J. Comput. Chem., 2008, DOI 10.1002/jcc.21163.
53. Chou, K. C.; Shen, H. B. ProtIdent: A web server for identifying proteases and their types by fusing functional domain and sequential evolution information. Biochem. Biopohys. Res. Commun., 2008, 376, 321-325.
54. Shen, H. B.; Chou, K. C. Identification of proteases and their types. Anal. Biochem., 2009, 385, 153-160.
55. Chou, K. C. A vectorized sequence-coupling model for predicting HIV protease cleavage sites in proteins. J. Biol. Chem., 1993, 268, 16938-16948.
56. Chou, K. C. Review: Prediction of HIV protease cleavage sites in proteins. Anal. Biochem., 1996, 233, 1-14.
57. Shen, H. B.; Chou, K. C. HIVcleave: a web-server for predicting HIV protease cleavage sites in proteins. Anal. Biochem., 2008, 375, 388-390.
58. Chou, K. C.; Shen, H. B. Signal-CF: a subsite-coupled and window-fusing approach for predicting signal peptides. Biochem. Biophys. Res. Commun., 2007, 357, 633-640.
59. Shen, H. B.; Chou, K. C. Sinal-3L: a 3-layer approach for predicting signal peptide. Biochem. Biophys. Res. Commun., 2007, 363, 297-303.
60. Wang, J. F.; Wei, D. Q.; Li, L.; Zheng, S. Y.; Li, Y. X.; Chou, K. C. 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. Biochem. Biophys. Res. Commun., 2007, 355, 513-519. (Corrigendum: ibid, 2007, Vol. 357, 330)
61. Wang, J. F.; Wei, D. Q.; Li, L.; Chou, K. C. Review: Pharmacogenomics and personalized use of drugs. Curr. Topics Med. Chem., 2008, 8, 1573-1579.
62. Wang, J. F.; Zhang, C. C.; Chou, K. C.; Wei, D. Q. Review: Structure of cytochrome P450s and personalized drug. Curr. Med. Chem., 2009, 16, 232-244.
63. Wang, J. F.; Zhang, C. C.; Yan, J. Y.; Chou, K. C.; Wei, D. Q. In Automation in Genomics and Proteomics: An Engineering Case-Based Approach, Chapter 11; Benson, R.; Alterovitz, G.; Marco-Ramoni, M.; Wiley: Boston, 2009.
64. Li, H.; Poulos, T. L. Conformational dynamics in cytochrome P450-substrate interactions. Biochimie, 1996, 78, 695-699.
65. Chou, K. C. In Frontiers in Medicinal Chemistry, Atta-ur-Rahman, Reitz, A. B., Ed.; Bentham Science Publishers: the Netherlands, 2006, Vol. 3, pp. 455-502.
66. Wei, D. Q.; Zhang, R.; Du, Q. S.; Gao, W. N.; Li, Y.; Gao, H.; Wang, S. Q.; Zhang, X.; Li, A. X.; Sirois, S.; Chou, K. C. Anti-SARS drug screeing by molecular docking. Amino Acids, 2006, 31, 73-80.
67. Wei, D. Q.; Sirois, S.; Du, Q. S.; Arias, H. R.; Chou, K. C. Theortical studies of Alzheimer's disease drug candidate [(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21) and its derivatives. Biochem. Biophys. Res. Commun., 2005, 338, 1059-1064.
68. Zhou, G. P.; Troy, F. A. 2nd NMR study of the preferred membrane orientation of polyisoprenols (dolichol) and the impact of their complex with polyisoprenyl recognition sequence peptides on membrane structure. Glycobiology, 2005, 15, 347-359.
69. Zhou, G. P.; Troy, F. A. NMR studies on how the binding complex of polyisoprenol recognition sequence peptides and polyisoprenols can modulate membrane structure. Curr. Protein Pept. Sci., 2005, 6, 399-411.
70. Wei, H.; Zhang, R.; Wang, C.; Zheng, H.; Chou, K. C.; Wei, D. Q. Molecular insights of SAH enzyme catalysis and their implication for inhibitor design. J. Theor. Biol., 2007, 244, 692-702.
71. Du, Q. S.; Wang, S.; Wei, D. Q.; Sirois, S.; Chou, K. C. Molecular modeling and chemical modification for finding peptide inhibitor against SARS CoV Mpro. Anal. Biochem., 2005, 337, 262-270.
72. Li, L.; Wei, D. Q.; Wang, J. F.; Chou, K. C. Computational studies of the binding mechanism of calmodulm with chrysin. Biochem. Biophys. Res. Commun., 2007, 358, 1102-1107.
73. Guo, X. L.; Li, L.; Wei, D. Q.; Zhu, Y. S.; Chou, K. C. Cleavage mechanism of the H5N1 hemagglutinin by trypsin and furin. Amino Acids, 2008, 35, 375-382.
74. Wang, S. Q.; Du, Q. S.; Zhao, K.; Li, A. X.; Wei, D. Q.; Chou, K. C. Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy. Amino Acids, 2007, 33, 129-135.
75. Du, Q. S.; Wang, S. Q.; Jiang, Z. Q.; Gao, W. N.; Li, Y. D.; Wei, D. Q.; Chou, K. C. Application of bioinformatics in search for cleavable peptides of SARS-CoV Mpro and chemical modification of octapeptides. Med. Chem., 2005, 1, 209-213.
76. Du, Q. S.; Sun, H.; Chou, K. C. Inhibitor design for SARS coronavirus main protease based on "distorted key theory". Med. Chem., 2007, 3, 1-6.
77. Wang, J. F.; Wei, D. Q.; Lin, Y.; Wang, Y. H.; Du, H. L.; Li, Y. X.; Chou, K. C. Insights from modeling the 3D structure of NAD(P)H-dependent D-xylose reductase of Pichia stipitis and its binding interactions with NAD and NADP. Biochem. Biophys. Res. Commun., 2007, 359, 323-329.
78. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian Genetic Algorithm and empirical binding free energy function. J. Comput. Chem., 1998, 19, 1639-1662.
79. Allen, M. P.; Wilson, M. R. Computer simulation of liquid crystals. J. Comput. Aided Mol. Des., 1989, 3, 335-353.
80. Wester, M. R.; Yano, J. K.; Schoch, G. A.; Yang, C.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human cytochrome P450 2C9 complexed with flurbiprotein at 2.0-A resolution. J. Biol. Chem., 2004, 279, 35630-35637.
81. Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Matak-Vinkovic, D.; Jhoti, H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 2003, 424, 464-468.
82. Chou, K. C.; Watenpaugh, K. D.; Heinrikson, R. L. A model of the complex between cyclin-dependent kinase 5 (Cdk5) and the activation domain of neuronal Cdk5 activation. Biochem. Biophys. Res. Commun., 1999, 259, 420-428.
83. Zhang, J.; Luan, C. H.; Chou, K. C.; Johnson, G. V. W. Identification of the N-terminal functional domain of Cdk5 by molecular truncation and computer modeling. Proteins., 2002, 48, 447-453.
84. Chou, K. C. Insights from modeling the 3D structure of the extracellular domain of alpha 7 nicotinic acetylcholine receptor. Biochem. Biophys. Res. Commun., 2004, 319, 433-438.
85. Wei, D. Q.; Du, Q. S.; Sun, H.; Chou, K. C. Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands. Biochem. Biophys. Res. Commun., 2006, 344, 1048-1055.
86. Wang, S. Q.; Du, Q. S.; Chou, K. C. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochem. Biophys. Res. Commun., 2007, 354, 634-640.